US 2026/0174798 A1 · ANTIBODY AGAINST BLOOD CANCER

Abstract

An antibody that recognizes HLA-DR or a functional fragment thereof, a chimeric antigen receptor that has the antibody or a functional fragment thereof, an immune cell expressing the chimeric antigen receptor, a multispecific antibody that includes the antibody or a functional fragment thereof and the antigen recognition site for immune cells, or a pharmaceutical composition containing these antibodies and the like.

Claims12

Dependent claims

A composition for treating a blood cancer, comprising:

an antibody that recognizes HLA-DR or a functional fragment thereof.

An antibody that recognizes HLA-DR or a functional fragment thereof, which has a feature described in one of following (a) to (i):

(a) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
1 to 3, respectively,
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
5 to 7, respectively;
(b) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
34 to 36, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
38 to 40, respectively;
(c) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
42 to 44, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
46 to 48, respectively;
(d) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
50 to 52, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
54 to 56, respectively;
(e) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
58 to 60, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(f) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
66 to 68, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(g) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
70 to 72, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(h) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
74 to 76, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
and
(i) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
66 to 68, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62, 78 and 64, respectively.

43 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/132,498Filed 22 Nov 2023

Priority

JP 2022-18856125 Nov 2022

Published

25 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
A61K 35/02
Medicinal preparations containing materials or reaction products thereof with undetermined constitution: from inanimate materials
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…

Abstract

Claims12

Dependent claims

A composition for treating a blood cancer, comprising:

an antibody that recognizes HLA-DR or a functional fragment thereof.

An antibody that recognizes HLA-DR or a functional fragment thereof, which has a feature described in one of following (a) to (i):

(a) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
1 to 3, respectively,
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
5 to 7, respectively;
(b) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
34 to 36, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
38 to 40, respectively;
(c) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
42 to 44, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
46 to 48, respectively;
(d) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
50 to 52, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
54 to 56, respectively;
(e) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
58 to 60, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(f) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
66 to 68, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(g) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
70 to 72, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
(h) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
74 to 76, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62 to 64, respectively;
and
(i) comprising
a heavy chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
66 to 68, respectively, and
a light chain variable region that includes complementarity-determining regions 1 to 3 containing amino acid sequences set forth in SEQ ID NOs:
62, 78 and 64, respectively.

43 more elements

Dependencies are inferred from the claim text.

Antibody against blood cancer

Life of this patent

Abstract

Claims12

Antibody against blood cancer

Life of this patent

Abstract

Claims12